

T-Cell Receptor Gene Rearrangement, PCR,
Tissue

## Overview

### **Useful For**

Determining whether a T-cell population is polyclonal or monoclonal using paraffin-embedded specimens

### **Method Name**

Polymerase Chain Reaction (PCR)

### **NY State Available**

No

# **Specimen**

## **Specimen Type**

Tissue, Paraffin

### **Specimen Required**

Specimen Type: Paraffin-embedded bone marrow aspirate clot or paraffin-embedded tissue

Container/Tube: Paraffin block

Specimen Volume: Minimum of 4 slides; 10 um preferred

## **Forms**

Molecular Pathology Test Request (T726)

### Specimen Minimum Volume

See Specimen Required

# **Reject Due To**

Bone marrow	Reject
biopsies	
Paraffin	
shavings	
Non-Formalin-f	
ixed/paraffin-	
embedded	
tissue samples	
Extracted DNA	
from another	
lab	



T-Cell Receptor Gene Rearrangement, PCR,
Tissue

Decalcified	
tissue	

# **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Tissue, Paraffin	Ambient (preferred)		
	Refrigerated		

## **Clinical & Interpretive**

#### Clinical Information

The T-cell receptor (TCR) genes (alpha, beta, delta, and gamma) are comprised of numerous, discontinuous coding segments that somatically rearrange to produce heterodimeric T-cell surface receptors, either alpha/beta (90%-95% of T cells) or gamma/delta (5%-10% of T cells). With rare exceptions (eg, some neoplastic B-lymphoid proliferations), other cell types retain the germline configuration of the TCR genes without rearrangement.

The marked diversity of somatic TCR-gene rearrangements is important for normal immune functions but also serves as a valuable marker to distinguish abnormal T-cell proliferations from reactive processes. A monoclonal expansion of a T-cell population will result in the predominance of a single TCR-gene rearrangement pattern. In contrast, reactive T-cell expansions are polyclonal (or multiclonal), with no single clonotypic population predominating in the population of T cells. These distributive differences in both TCR sequence and genomic rearrangement fragment sizes can be detected by molecular techniques (ie, polymerase chain reaction) and used to determine if a population of T cells shows monoclonal or polyclonal features.

## **Reference Values**

An interpretive report will be provided.

Positive, negative, or indeterminate for a clonal T-cell population

#### Interpretation

An interpretive report will be provided.

Results will be characterized as positive, negative, or indeterminate for a clonal T-cell population.

In the appropriate clinicopathologic setting, a monoclonal result is associated with a neoplastic proliferation of T cells (see Cautions).

### **Cautions**

To determine the significance of the result, it must always be interpreted in the context of other clinicopathologic information.

The interpretation of the presence or absence of a predominant T-cell receptor (TCR)-gene rearrangement profile is



T-Cell Receptor Gene Rearrangement, PCR,
Tissue

sometimes subjective.

The detection of a clonal TCR-gene rearrangement by this test is not necessarily synonymous with the presence of a T-cell neoplasm. False-positive results can occur because of the sensitivity of polymerase chain reaction (PCR) technique and the problem of nonuniform (skewed) amplification of target T-cell gene rearrangements. The latter problem can occur when the total T-cell number in a sample is limited or due to physiologic skewing of the T-cell repertoire, as seen with aging, post transplantation, or T-cell reactions in autoimmune or (nonlymphoid) malignancies. False-negative results can occur for many reasons, including tissue sampling, poor amplification, or failure to detect a small minority of T-cell gene segment rearrangements with the use of consensus PCR primers. In some cases, an indeterminate or equivocal result will occur because the pattern of gene rearrangements is abnormal (compared to typical polyclonal T-cell processes), but not definitive, for a monoclonal T-cell population. In these situations, distinction of a small monoclonal subpopulation from an overrepresented, but reactive, population may not be possible.

#### **Clinical Reference**

- 1. van Heijst JM, Ceberio I, Lipuma LB, et al. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nature Medicine. 2013;19(3):372-378
- 2. Liu H, Bench AJ, Bacon CM, et al. A practical strategy for the routine use of BIOMED-2 PCR assays for detection of B-and T-cell clonality in diagnostic haematopathology. Br J Haematol. 2007;138(1):31-43
- 3. Van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 concerted action BHM4-CT98-3936. Leukemia. 2007;21(2):201-206
- 4. Bruggemann M, White H, Gaulard P, et al. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia. 2007;21(2):215-221
- 5. Davies K, Staniforth J, Haowei Xie W, et al. Advances in the assessment of T-cell clonality. Diag Histopathol. 2020;26(9):388-397

### **Performance**

## **Method Description**

Genomic DNA is extracted from the tissue source. T-cell receptor beta and T-cell receptor gamma loci (official designations *TRB* and *TRG*, respectfully) are amplified by polymerase chain reaction (PCR) using a multiplex primer method based on the BIOMED-2 strategy. Specific primers are labeled with fluorochrome dyes, permitting precise fragment sizing of PCR products by capillary gel electrophoresis (Applied Biosystems 3500xL Genetic Analyzer). Each amplified locus is assessed for gene rearrangement patterns, and an overall interpretation of the assay is made with regard to the presence or absence of a monoclonal population. (Langerak AW, Groenen PJ, Bruggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26[10]:2159-2171)

### PDF Report

No

### Day(s) Performed

Monday through Friday



T-Cell Receptor Gene Rearrangement, PCR,
Tissue

## Report Available

1 to 8 days

## **Specimen Retention Time**

DNA: 1 year; Tissue slides: 3 months

## **Performing Laboratory Location**

Mayo Clinic Jacksonville Clinical Lab

## **Fees & Codes**

#### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

### **Test Classification**

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

## **CPT Code Information**

81340-TCB (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, PCR)

81342-TCG (T cell receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)

### **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
TCGET	T Cell Receptor Gene Rearrange, Ts	21751-3

Result ID	Test Result Name	Result LOINC® Value
38343	Final Diagnosis:	22637-3
610557	Signing Pathologist	19139-5